Document Type
Article
Publication Date
11-1-2024
Abstract
There is emerging evidence that the endocannabinoid system (ECS) plays a significant role in the pathophysiology of many psychiatric disorders, including attention deficit hyperactivity disorder (ADHD). Increasing evidence suggests that a number of neurobiological correlates between endogenous cannabinoid function and cognitive dysfunction are seen in ADHD, making the ECS a possible target for therapeutic interventions. Cannabis use and cannabis use disorder are more prevalent in individuals with ADHD, compared to the general population, and there is growing popular perception that cannabis is therapeutic for ADHD. However, the relationship between cannabis use and ADHD symptomology is poorly understood. Further understanding of the role of the ECS in ADHD pathophysiology and the molecular alterations that may be a target for treatment is needed. To further the science on this emerging area of research, this scoping review describes the preclinical and clinical evidence seeking to understand the relationship between the ECS and ADHD.
Recommended Citation
Ryan, Jennie; Fruchtman, Mitchell; Sparr-Jaswa, Andrea; Knehans, Amy; and Worster, Brooke, "Attention Deficit Hyperactivity Disorder, Cannabis Use, and the Endocannabinoid System: A Scoping Review" (2024). Department of Medicine Faculty Papers. Paper 463.
https://jdc.jefferson.edu/medfp/463
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.
PubMed ID
39267530
Language
English
Comments
This article is the author's final published version in Developmental psychobiology, Volume 66, Issue 7, November 2024, Article number e22540.
The published version is available at https://doi.org/10.1002/dev.22540.
Copyright © 2024 The Author(s)